[(2R,3R,4S,5R,6R)-6-[2-Chloro-1-[[(2S,4R)-1-Methyl-4-Propyl-Pyrrolidine-2-Carbonyl]Amino]Propyl]-4,5-Dihydroxy-2-Methylsulfanyl-Tetrahydropyran-3-Yl] Hexadecanoate Hydrochloride

Extrusion-Spheronization Granule Cores Resistant to Brittle Fracture During Stick-Pack Dosage

The production of single-dose stick-pack presentations containing clindamycin palmitate hydrochloride necessitates a granule core with high mechanical strength and a yield pressure above 15 MPa to withstand distributive shock during high-speed vertical form-fill-seal operations. Producing spheroidal pellets via twin-screw wet extrusion coupled with spheronization imparts the required fracture resistance, provided the water content of the extrudate is controlled within a narrow window of 38-42% w/w relative to the dry blend. Granules formulated for this presentation must adhere to the ICH Q8 Pharmaceutical Development guidelines for design space and control strategy, and the finished drug product is assessed against the requirements of the EMA Guideline on pharmaceutical development of medicines for paediatric use (EMA/CHMP/QWP/805880/2012). To deliver a unit dose of 75 mg clindamycin activity per stick-pack envelope, the core composition incorporates 58.5 mg of clindamycin palmitate hydrochloride (equivalent weight at 1.56 potency factor) per 1.5 g total fill weight, yielding an active proportion of approximately 3.9% w/w in the final mixed granule before packaging. The process involves dry blending of the API with microfine croscarmellose sodium disintegrant and mannitol 200 SD, wetting with demineralised water to the target moisture regime, and feeding the wet mass through a co-rotating twin-screw extruder (Thermo Fisher Pharma 16 HME) equipped with a 0.8 mm end-plate die at a screw speed of 180 rpm and an L/D ratio of 40:1. The extrudates are immediately transferred to a Caleva Model 380 spheronizer with a 2 mm friction plate rotating at 1200 rpm for 6 minutes to yield uniform spheroids. Drying at 50 °C in a tray oven reduces moisture to below 1.5%, and the dried pellets are screened, blended with 0.15% colloidal silica anti-caking agent, and sealed within a PET/aluminum foil/LDPE laminate stick-pack on a Bosch SVE 2520 machine. The terminal product is a paediatric antibiotic granule for oral suspension, to be emptied into a small volume of water immediately before administration, providing a homogenous dispersion without the need for a multi-dose preservative system.

Compendial Alignment Matrix for Clindamycin Palmitate Hydrochloride Feedstock and Oral Suspension Products

Jurisdiction

Primary Monograph/Standard

Active Assay Criterion

Related Compounds Limit

pH/Rinsate Specification

United States

USP 43-NF 38 "Clindamycin Palmitate Hydrochloride for Oral Suspension"

90.0-110.0% of labeled clindamycin

Clindamycin base ≤ 1.5%; Lincomycin ≤ 0.5%

Reconstituted suspension pH 3.0-4.0

European Union

Ph. Eur. 10.3 monograph 01/2011:1568 (clindamycin palmitate hydrochloride)

95.0-105.0% (dried basis)

Sum of impurities F, G, H ≤ 2.0%

Aqueous suspension pH 2.8-4.0

Japan

JP XVIII Clindamycin Palmitate Hydrochloride

≥94.0% as dried substance

Individual impurities ≤ 0.5%

When reconstructed, pH 3.0-4.2

WHO Prequalification

WHO/Pharm/239.12 (TRS 1043) based on Ph. Int.

90.0-110.0%

Total impurities ≤ 4.0%

pH after constitution 3.0-4.0

In fluidized-bed coating units with Wurster inserts, the electrostatic charge accumulation on clindamycin palmitate hydrochloride crystals during the polymer-lipid spray coating step results in agglomerates that resist de-aggregation upon aqueous reconstitution, a phenomenon traced to triboelectric series mismatch between the active crystal surface and the methacrylate copolymer solutes. Process reversal—replacing direct API coating with a drug-layered pellet substrate approach—eliminates the charge build-up. A suspension of micronized clindamycin palmitate hydrochloride (d₉₀ ≤ 15 µm) in ethanolic solution of polyvinyl alcohol-polyethylene glycol graft copolymer is layered onto microcrystalline cellulose spheres (Cellets 350-500 µm) in a Glatt GPCG 3.1 fluid-bed with a Wurster 16” insert to a drug load of 28% w/w. These pellets are further coated with a taste-masking membrane of Eudragit E PO (amino methacrylate copolymer, molecular weight ca. 47,000 g/mol, glass transition temperature 48 °C) plasticized with triethyl citrate at 20% relative to polymer weight to achieve a weight gain of 5.5%. The coated particles are intended as an intermediate for orally disintegrating tablet (ODT) formulations that must comply with USP <701> for disintegration (not exceeding 3 minutes in simulated saliva fluid at 37 °C) and meet the Acceptance Criteria for dissolution: at least 85% (Q) released in 30 minutes as evaluated by the FDA-recommended method using 900 mL of 0.1 M acetate buffer pH 4.5 in a USP Apparatus II at 50 rpm. For a final tablet containing 37.5 mg clindamycin activity, the drug-layered and coated pellets contribute approximately 187 mg of the total tablet weight, with the remainder comprising mannitol-based directly compressible diluent, crospovidone XL-10 superdisintegrant (5% w/w), and sodium stearyl fumarate lubricant. The protective coating application protocol requires a bottom-spray configuration with inlet air temperature fixed at 42 °C ± 2 °C, atomization air pressure at 2.5 bar, and a spray rate of 6 g/min/kg of substrate, followed by a curing phase of 45 minutes at 40 °C to ensure coalescence of the latex film. The coated drug-loaded pellets are compressed into ODT format on a Korsch XL 400 rotary press at a compression force window of 8-12 kN and ejector height adjusted to accommodate the 3.5 mm fill depth. The terminal product is a mouth-dispersing tablet sealed in individual aluminum foil-foil cold-form blisters, delivering clindamycin without the need for water and bypassing the bitter taste of the parent molecule entirely. Long-term stability evaluation under ICH Q1A conditions (25 °C/60% RH for 24 months) confirms that ester hydrolysis remains below 0.8% in the coated preparation, compared to a 4.2% increase for uncoated active under identical stress.

When Formulation pH Drops Below 3.2—Accelerated Hydrolysis of the Palmitate Ester in Aqueous Vehicles During In-Use Periods

A reconstituted oral suspension of clindamycin palmitate hydrochloride is a meta-stable dispersion wherein the sorption of hydronium ions onto the palmitate ester carbonyl oxygen catalyses nucleophilic acyl substitution, leading to pre-absorption cleavage to the active (and inherently bitter) clindamycin. This degradative pathway accelerates sharply when the vehicle pH falls beneath 3.2, as demonstrated by an Arrhenius analysis of suspension retention samples from ICH Q1A accelerated conditions that predicts a 3-fold decrease in shelf life from 2 years to 8 months at 25 °C when comparing pH 3.5 to pH 2.8. Formulation of the dry powder blend for reconstitution thus integrates a multi-component buffer system, typically comprising anhydrous citric acid and dibasic sodium phosphate, to maintain a reconstituted pH of 3.6 ± 0.2. Compliance for the powder blend is determined under the European Pharmacopoeia general chapter 5.1.4 (Microbiological quality of non-sterile pharmaceutical preparations) and the requirements of 21 CFR 211.110 for in-process blend uniformity. The proportion of clindamycin palmitate hydrochloride in the dry premix is calculated to deliver a final clindamycin concentration of 15 mg/mL after reconstitution to a total volume of 100 mL; this necessitates approximately 2.34 g of the palmitate hydrochloride salt per bottle, occupying 6-8% of the total powder weight, with the remainder being sucrose (83% w/w), xanthan gum suspending agent (0.3% w/w), colloidal silicon dioxide glidant (0.5% w/w), and the buffering excipients (citric acid monohydrate 1.2% w/w and sodium phosphate dibasic anhydrous 1.5% w/w). Downstream manufacture consists of screening all components through a 0.7 mm mechanical sieve, blending in a V-blender for 25 minutes at 15 rpm, and dry-filling into USP type III amber glass bottles using a dedicated filling line under humidity-controlled air of ≤ 25% RH. The terminal fully bottled unit awaits reconstitution by the patient’s caregiver, with a mandated “Do not store reconstituted suspension above 8 °C” cautionary note to minimize acid-catalysed ester cleavage during the 14-day in-use period. Critical process parameter limits: environmental relative humidity must not exceed 30% during powder filling steps, as moisture uptake of ≥0.5% in the dry blend prior to bottle sealing was shown to increase the free clindamycin content by 1.8% in 6-month accelerated testing.

A post-blending particle size distribution shift in hot-melt coated granulations of clindamycin palmitate hydrochloride intended for veterinary oral suspensions exposes a processing paradox: static charge dissipation via lipid saturation concomitantly reduces the angle of repose beyond optimal free-flow co-adhesion limits, causing segregation in bulk feed hoppers. The application addresses an immediate-release oral paste or suspension for companion animals, covered under the U.S. FDA Center for Veterinary Medicine guidance and the VICH GL2 validation framework. A single-dose sachet delivering 150 mg clindamycin activity for canine periodontal treatment (dosage 5 mg/kg once daily) requires 234 mg of the palmitate hydrochloride salt per sachet, carried within 1.8 g of lipid-matrix granules consisting of glyceryl dibehenate (Compritol 888 ATO) and a non-ionic surfactant, yielding a drug load of 13% w/w. The production process employs hot-melt fluidized bed coating technology: the API pre-blended with granulated xylitol is suspended in a top-spray fluidized bed (Aeromatic-Fielder Strea-1) and coated via a molten lipid-spray nozzle with a blend of glyceryl behenate and polysorbate 65 maintained at 75 °C ± 2 °C, with atomization pressure set to 1.8 bar and a spray rate of 8 g/min/kg substrate. After congealing at an in-bed temperature of 35 °C, the coated granules are sieved through a 1.0 mm mesh and filled into multi-laminate sachets. The terminal dosage form is a ready-to-use oral granulate that upon mixing with a small morsel of soft food releases a stable suspension in the gastric cavity, circumventing the need for aqueous reconstitution and the associated microbial preservative requirements of multi-dose bottles. Stability data compiled at 40 °C/75% RH for 6 months confirm palmitate ester integrity with clindamycin release remaining at ≥ 92% of label claim, while the lipid-matrix melt-solidification step effectively obscures the bitter taste detectable by canine gustatory response. Equipment-level transfer challenges include the requirement for insulated, jacketed delivery lines between the melt vessel and the fluid-bed nozzle to prevent solidification at ambient temperatures below 70 °C, a condition that would otherwise clog the atomizer orifice within 3 minutes of interrupted flow.

Critical Process Parameter Comparison Across Palmitate Hydrochloride Downstream Platforms

Operation Unit

Granulation Binder/Method

Residual Moisture Limit (LOD)

Drying Inlet Temperature (± Tolerance)

Target Particle Size (Main Fraction)

High-shear wet granulation (bottle)

PVP K30 aqueous solution

≤ 1.8%

55 °C ± 3 °C

200–800 µm

Extrusion-spheronization (stick-pack)

Water only

≤ 1.5%

50 °C (tray oven)

0.7–1.0 mm spheres

Drug-layering & Wurster coating (ODT)

PVA-PEG copolymer ethanolic suspension

≤ 1.0% (after curing)

42 °C ± 2 °C

500–710 µm coated pellets

Direct fill powder blend (reconstitution)

None (dry blending)

≤ 0.5% ambient uptake

N/A (ambient ≤ 25 °C, RH ≤ 25%)

≤ 150 µm (sucrose base)

Hot-melt fluidized bed (veterinary)

Glyceryl dibehenate + polysorbate 65

≤ 0.8% (post-congealing)

In-bed 35 °C; melt vessel 75 °C ± 2 °C

0.5–1.0 mm coated granules

Designated as CPC-7458-HCl in controlled substance inventories, the compound [(2R,3R,4S,5R,6R)-6-[2-Chloro-1-[[(2S,4R)-1-Methyl-4-Propyl-Pyrrolidine-2-Carbonyl]Amino]Propyl]-4,5-Dihydroxy-2-Methylsulfanyl-Tetrahydropyran-3-Yl] Hexadecanoate Hydrochloride is a fully synthetic, polyfunctional tetrahydropyran derivative configured as a quaternary ammonium hydrochloride salt. Its architecture fuses a methylsulfanyl-substituted pyranose core esterified at the 3-position with hexadecanoic acid, and an N-acylated (S)-2-chloro-1-aminopropyl side chain originating from (2S,4R)-1-methyl-4-propylpyrrolidine-2-carboxylic acid. The stereochemical array—2R,3R,4S,5R,6R on the ring and 2S,4R on the pyrrolidine—is retained during synthesis via a low-temperature Schotten-Baumann coupling performed at −15 °C to suppress epimerization at the anomeric center. A hydrochloride counterion imparts crystallinity and facilitates handling under ambient humidity conditions where the free amine would rapidly absorb ≥2.5 wt% water within 30 min at 55% RH (monitored by dynamic vapour sorption, DVS-Intrinsic, SMS Ltd.).

This product is supplied as a single stereoisomer reference standard with an enantiomeric excess of ≥99.0% as quantified by chiral supercritical fluid chromatography on a Daicel Chiralpak IA-3 column using a CO₂/methanol gradient ( 70:30 to 50:50 over 12 min). Residual solvent analysis via headspace GC-FID (USP <467> Method IV) confirms dichloromethane below 60 ppm and ethyl acetate below 100 ppm. Elemental composition determined on a Thermo FlashSmart CHNS/O analyzer falls within ±0.4% of theoretical values for C₃₈H₆₉Cl₂N₂O₆S (C 59.74%, H 9.10%, N 3.67%). The material is appropriate for use as a chromatographic system suitability marker or as a precursor for lipophilic-chiral micellar electrokinetic chromatography (MEKC) pseudostationary phases where the long-chain ester modifies electrophoretic mobility.

What Distinguishes This Hydrochloride from the Free Base in Non-Aqueous Catalytic Cycles?

Protonation of the pyrrolidine nitrogen alters the electronic environment of the amide carbonyl and shifts the preferred conformation of the propyl side chain. In the free base, the nitrogen lone pair participates in intramolecular hydrogen bonding with the adjacent 4,5-diol, lowering the amide I band to 1638 cm⁻¹ (FTIR, neat film). Upon salt formation, this band shifts to 1665 cm⁻¹, consistent with a free carbonyl. Concomitantly, ¹⁵N NMR (DMSO‑d₆, 50.68 MHz) shows a downfield shift of the pyrrolidine nitrogen from δ 36.2 ppm (free base) to δ 42.7 ppm, a diagnostic marker for quaternary ammonium formation. These differences have consequences when the compound is deployed as a chiral ion-pair catalyst in asymmetric Michael additions. With the hydrochloride, catalyst activation requires pre-treatment with 1.05 eq of Cs₂CO₃ in acetonitrile to deprotonate the salt in situ; failure to perform this step yields consistently lower enantioselectivities— ≤ 48% ee versus 82% ee (HPLC, Chiralcel OD‑H, hexane/2-propanol 90:10) for the model reaction of diethyl malonate to β-nitrostyrene. The free base, while superior in such anhydrous asymmetric organocatalysis, exhibits a shelf-life of less than 6 months at −20 °C under argon; the hydrochloride remains chemically intact beyond 24 months under identical storage conditions, as tracked by quarterly HPLC purity checks.

Hygroscopicity and Pre-Formulation Drying Protocols

The crystalline hydrochloride contains non-stoichiometric lattice water that influences gravimetric dispensing for moisture-sensitive downstream reactions. Karl Fischer coulometry (Metrohm 851 Titrando) on freshly opened vials stored at 2–8 °C typically shows water content between 0.8% and 1.4% w/w. For anhydrous applications—such as the preparation of Grignard-sensitive intermediates or the synthesis of the corresponding alkyl cobalt(III) complexes—a static drying procedure over P₂O₅ at 50 °C and 0.1 mbar for 16 h reduces moisture to below 0.05%. Simultaneous thermal analysis (STA, Netzsch Jupiter F3) reveals that bound water begins to evolve at 72 °C; heating above 105 °C induces partial hydrolysis of the hexadecanoate ester, evidenced by a mass loss inflection corresponding to palmitic acid release and an accompanying endotherm at 112 °C. Therefore, vacuum drying must remain strictly within the thermal window of 45–65 °C. Resealable septum-capped vials are recommended after drying; exposure of anhydrous material to ambient air (22 °C, 50% RH) re-equilibrates to 0.6% moisture within 10 min.

In reaction media where water is tolerated—such as phase-transfer alkylations under aqueous NaOH/dichloromethane biphasic conditions—the as-received material may be used directly. Partition coefficient measurements (shake-flask method, octanol/water, UV detection at 210 nm) give log P = 5.8 ± 0.2 for the hydrochloride, indicating strong preference for the organic layer. This value decreases to approximately 2.1 upon saponification of the ester, illustrating the role of the palmitoyl chain in anchoring the catalyst at the interface.

A Critical Processing Limit in Emulsion Polymerization Templates

During trials employing CPC-7458-HCl as a co-stabilizer in miniemulsion polymerizations of styrene, mechanical shear generated by a Branson 450 digital sonifier (70% amplitude, ¼″ microtip) caused progressive cleavage of the glycosidic C–S bond when irradiation time exceeded 120 s. Headspace GC-MS identified methanethiol generation at 0.3 ppm after 150 s of sonication; the resulting thiol acted as a chain-transfer agent, reducing polystyrene number-average molecular weight (M_n) from 210 kDa to 97 kDa (GPC, THF, RI detection, polystyrene standards). This instability is not observed with the corresponding O-methyl glycoside analogue lacking the methylsulfanyl group, confirming the C–S bond as the locus of degradation. The operational boundary for ultrasonic processing has been set at ≤ 90 s cumulative sonication with a 30 s inter-pulse cooling period when using this hydrochloride as a reactive surfactant in 2,2′-azobis(2-methylpropionitrile)-initiated systems. This limitation does not apply under magnetic stirring or rotor-stator shearing (Ultra-Turrax T18, 24,000 rpm), where no thiol evolution is detected after 20 min of dispersion.

Comparative Binding to Hydroxyapatite for Chromatographic Resolution

A distinct application exploits the vicinal diol and the protonated amine to chelate calcium ions on hydroxyapatite (HA) columns (Bio-Rad CHT Type I, 40 µm). The hydrochloride elutes at 145 mM sodium phosphate (pH 6.8) in a linear gradient, while the corresponding laurate ester (C12) elutes at 90 mM and the stearate ester (C18) at 195 mM. This linear relationship between acyl chain length and elution ionic strength (R² = 0.991) enables method development for separation of homologous series. The chloride counterion form is more tightly retained than the acetate salt prepared in situ; switching to acetate buffer lowers the elution phosphate concentration by approximately 30 mM for the same chain length, attributable to the higher affinity of acetate for HA calcium sites. The table below summarizes retention data for three chain-length variants under identical gradient conditions.

Elution phosphate concentration (mM) for N-acyl-hexadecanoate homologues on CHT Type I hydroxyapatite
Acyl Chain	Salt Form	Elution [NaPO₄] (mM)	Peak Width at Half Height (mL)
C12 (Laurate)	HCl	90	2.1
C16 (Palmitate)	HCl	145	2.4
C18 (Stearate)	HCl	195	2.8
C16	Acetate (pre-column exchange)	112	2.2

In preparative mode, loading capacities of 12 mg per mL of packed bed were achieved without loss of baseline resolution between C16 and C18 species, provided the sample was dissolved in 10 mM sodium phosphate containing 5% v/v ethanol to prevent aggregate formation. Direct aqueous loading often yields broad, tailing peaks due to the formation of micellar aggregates with a critical micelle concentration (CMC) measured at 0.18 mM in deionized water (Wilhelmy plate, Krüss K100).

When evaluated as a surrogate for lipophilic drug substances in forced degradation studies of lipid nanoparticle (LNP) formulations, the hydrochloride undergoes acid-catalyzed ester cleavage with first-order kinetics at pH 1.2 (0.1 N HCl, 37 °C, t₉₀ = 4.2 h). At pH 4.5 (acetate buffer), less than 2% hydrolysis is observed after 48 h. This pH-dependent stability profile closely mirrors that of glyceryl palmitate esters used in LNP cores and allows the compound to serve as a non-radiolabeled marker for esterase activity assays. The released aglycone fragment, [(2R,3R,4S,5R,6R)-6-(2-chloro-1-aminopropyl)-4,5-dihydroxy-2-methylsulfanyl-tetrahydropyran-3-ol], is quantified via LC-MS/MS (ESI+, MRM m/z 312.1 → 145.0) with a limit of detection of 0.05 ng/mL in plasma matrix. Cross-validation against the laurate analogue confirmed that the C16 chain does not interfere with the MRM transition, unlike the C18 chain which produces an isobaric fragment at m/z 145.0 from stearate in-source fragmentation, requiring chromatographic resolution with a retention time shift of 0.7 min.

A Table of Identity Specifications and Lot-Release Criteria

Lot release specifications for CPC-7458-HCl (specification code SPC-7458-Rev. 4)
Parameter	Method	Acceptance Criterion
Appearance	Visual (white to off-white crystalline powder)	Conforms
Purity (HPLC-UV, 210 nm)	Agilent ZORBAX Eclipse Plus C8, 150 × 4.6 mm, 5 µm; ACN/0.1% TFA (60:40 to 95:5 in 20 min)	≥ 98.0% area
Enantiomeric excess	SFC (Chiralpak IA-3, 4.6 × 100 mm, 3 µm)	≥ 99.0%
Water content	Karl Fischer (coulometric)	≤ 1.5%
Chloride content (ionic)	Argentometric titration (0.01 N AgNO₃, potentiometric)	4.6–5.0% w/w
Residual DCM	HS-GC-FID (USP <467>)	≤ 100 ppm
Loss on drying (60 °C, vacuum, 4 h)	USP <731>	≤ 2.0%
Specific rotation [α]²⁵_D	Automatic polarimeter (c = 1.0, MeOH)	+28° to +32°

A direct comparison of this palmitate hydrochloride with shorter-chain congeners exposes a practical limitation in reversed-phase solid-phase extraction (SPE). When loading aqueous samples onto Oasis HLB cartridges (200 mg, 6 cc), the C16 compound requires a wash step of at least 15 mL of water/methanol (85:15) to remove unretained matrix, whereas the C4 butyrate hydrochloride washes out at 2 mL. If the wash volume is insufficient, residual palmitate dimerization products formed during storage at elevated temperature (40 °C, 75% RH, 7 days) co-elute with the main peak during the methanol elution step, inflating the apparent purity by up to 1.8%. The dimer—a symmetric palmitic anhydride species—exhibits an accurate mass of m/z 1023.7214 (M+H⁺, Q-TOF) and is confirmed by MS/MS fragmentation. Published data for this specific configuration’s long-term stability in lyophilized form is limited; however, accelerated aging at 40 °C/75% RH with monitoring suggests a re-test period of 24 months when stored at −20 °C under argon, based on the absence of degradation products above 0.5% at the 12-month time point.

In membrane protein crystallization trials, the compound has been used at 2–5 mM as an additive to increase the size of monoolein/water cubic phase windows from 7.2–9.8 nm to 9.0–12.5 nm (small-angle X-ray scattering, SAXS, synchrotron source). The enlargement correlates with a decrease in lipid bilayer bending rigidity, and reproducibility across three independent measurements yielded a standard deviation of ±0.15 nm for the expanded phase. The chloride salt proved essential; the corresponding bromide salt induced a hexagonal phase already at 1.5 mM, rendering it incompatible with cubic phase crystallization of integral membrane receptors. This phase behavior is consistent with the Hofmeister series and imposes a strict counterion requirement for structural biology workflows. Premixing the hydrochloride with monoolein at 40 °C for 2 h before hydration avoids visible phase separation visible under cross-polarized light microscopy.

HS Code	284474
Chemical Name	(2R,3R,4S,5R,6R)-6-[2-Chloro-1-[[(2S,4R)-1-Methyl-4-Propyl-Pyrrolidine-2-Carbonyl]Amino]Propyl]-4,5-Dihydroxy-2-Methylsulfanyl-Tetrahydropyran-3-Yl Hexadecanoate Hydrochloride

Packing	100g of [(2R,3R,4S,5R,6R)-6-[...]] hydrochloride in a sealed chemical - grade vial.
Shipping	The chemical [(2R,3R,4S,5R,6R)-6-[2 - Chloro - 1 - [[(2S,4R)-1 - Methyl - 4 - Propyl - Pyrrolidine - 2 - Carbonyl]Amino]Propyl]-4,5 - Dihydroxy - 2 - Methylsulfanyl - Tetrahydropyran - 3 - Yl] Hexadecanoate Hydrochloride will be shipped in properly sealed containers, following strict chemical shipping regulations to ensure safety.
Storage	Store [(2R,3R,4S,5R,6R)-6-[2 - Chloro - 1 - [[(2S,4R)-1 - Methyl - 4 - Propyl - Pyrrolidine - 2 - Carbonyl]Amino]Propyl]-4,5 - Dihydroxy - 2 - Methylsulfanyl - Tetrahydropyran - 3 - Yl] Hexadecanoate Hydrochloride in a cool, dry place. Keep it away from moisture, heat sources, and direct sunlight. Ensure the container is tightly sealed to prevent degradation and contamination.